Logo image of YS

YS BIOPHARMA CO LTD (YS) Stock Fundamental Analysis

NASDAQ:YS - Nasdaq - KYG9845F1090 - Common Stock - Currency: USD

1.02  +0.11 (+12.45%)

After market: 1.07 +0.05 (+4.9%)

Fundamental Rating

2

YS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. YS has a bad profitability rating. Also its financial health evaluation is rather negative. YS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

YS had negative earnings in the past year.
YS Yearly Net Income VS EBIT VS OCF VS FCFYS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -50M -100M -150M -200M -250M

1.2 Ratios

YS's Return On Assets of -17.59% is amongst the best of the industry. YS outperforms 83.77% of its industry peers.
YS has a Return On Equity of -50.88%. This is in the better half of the industry: YS outperforms 66.32% of its industry peers.
Industry RankSector Rank
ROA -17.59%
ROE -50.88%
ROIC N/A
ROA(3y)-6.91%
ROA(5y)N/A
ROE(3y)-18.75%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
YS Yearly ROA, ROE, ROICYS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -10 -20 -30

1.3 Margins

YS's Gross Margin of 77.68% is amongst the best of the industry. YS outperforms 86.18% of its industry peers.
The Profit Margin and Operating Margin are not available for YS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
YS Yearly Profit, Operating, Gross MarginsYS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 20 -20 40 -40 60

More info and screens

1

2. Health

2.1 Basic Checks

YS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, YS has more shares outstanding
Compared to 1 year ago, YS has a worse debt to assets ratio.
YS Yearly Shares OutstandingYS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 20M 40M 60M 80M
YS Yearly Total Debt VS Total AssetsYS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

YS has an Altman-Z score of -0.65. This is a bad value and indicates that YS is not financially healthy and even has some risk of bankruptcy.
YS has a Altman-Z score (-0.65) which is in line with its industry peers.
A Debt/Equity ratio of 0.65 indicates that YS is somewhat dependend on debt financing.
YS has a Debt to Equity ratio of 0.65. This is in the lower half of the industry: YS underperforms 75.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Altman-Z -0.65
ROIC/WACCN/A
WACC7.73%
YS Yearly LT Debt VS Equity VS FCFYS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 1.41 indicates that YS should not have too much problems paying its short term obligations.
YS has a Current ratio of 1.41. This is amonst the worse of the industry: YS underperforms 83.77% of its industry peers.
YS has a Quick Ratio of 1.09. This is a normal value and indicates that YS is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of YS (1.09) is worse than 86.18% of its industry peers.
Industry RankSector Rank
Current Ratio 1.41
Quick Ratio 1.09
YS Yearly Current Assets VS Current LiabilitesYS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for YS have decreased strongly by -9348.42% in the last year.
EPS 1Y (TTM)-9348.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-946.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 27.80% on average over the next years. This is a very strong growth
Based on estimates for the next years, YS will show a very strong growth in Revenue. The Revenue will grow by 85.19% on average per year.
EPS Next Y19.72%
EPS Next 2Y31.7%
EPS Next 3Y27.8%
EPS Next 5YN/A
Revenue Next Year-6.61%
Revenue Next 2Y9.01%
Revenue Next 3Y27.69%
Revenue Next 5Y85.19%

3.3 Evolution

YS Yearly Revenue VS EstimatesYS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 500M 1B 1.5B 2B 2.5B
YS Yearly EPS VS EstimatesYS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0 -0.1 -0.2 -0.3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for YS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for YS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YS Price Earnings VS Forward Price EarningsYS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YS Per share dataYS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as YS's earnings are expected to grow with 27.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.7%
EPS Next 3Y27.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for YS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

YS BIOPHARMA CO LTD

NASDAQ:YS (5/24/2024, 8:06:00 PM)

After market: 1.07 +0.05 (+4.9%)

1.02

+0.11 (+12.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-19 2024-04-19/bmo
Earnings (Next)N/A N/A
Inst Owners1.72%
Inst Owner Change-23.27%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap192.10M
Analysts84.44
Price Target4.26 (317.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.47%
PT rev (3m)-19.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26.45%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-85.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.02
P/FCF N/A
P/OCF N/A
P/B 2.5
P/tB 2.88
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.5
BVpS0.41
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.59%
ROE -50.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.68%
FCFM N/A
ROA(3y)-6.91%
ROA(5y)N/A
ROE(3y)-18.75%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.41
Quick Ratio 1.09
Altman-Z -0.65
F-ScoreN/A
WACC7.73%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9348.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-946.42%
EPS Next Y19.72%
EPS Next 2Y31.7%
EPS Next 3Y27.8%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-6.61%
Revenue Next 2Y9.01%
Revenue Next 3Y27.69%
Revenue Next 5Y85.19%
EBIT growth 1Y-24931.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.13%
EBIT Next 3Y41.56%
EBIT Next 5YN/A
FCF growth 1Y-38958.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29655.5%
OCF growth 3YN/A
OCF growth 5YN/A